SEC Form D Coverage: Biohaven Pharmaceutical Holding Co $80.00 million Fundraising. Vladimir Coric Submitted Nov 10 Form D

Pharmaceuticals Biohaven Pharmaceutical Holding Co Ltd. - Vladimir Coric

Biohaven Pharmaceutical Holding Co Financing

Biohaven Pharmaceutical Holding Co Ltd., just filed form D regarding $80.00 million equity financing. This is a new filing. Biohaven Pharmaceutical Holding Co was able to fundraise $40.00 million so far. That is 50.00% of the fundraising. The total financing amount was $80.00 million. The private financing document was filed on 2016-11-10. The reason for the financing was: Series A Preferred Shares. The fundraising still has about $40.00 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Biohaven Pharmaceutical Holding Co is based in Connecticut. The firm’s business is Pharmaceuticals. The form was filed by Vladimir Coric CEO. The company was incorporated in 2013. The filler’s address is: 234 Church Street, Suite 304, New Haven, Ct, Connecticut, 06510. Vladimir Coric, M.D. is the related person in the form and it has address: 234 Church Street, Suite 304, New Haven, Ct, Connecticut, 06510. Link to Biohaven Pharmaceutical Holding Co Filing: 000090866216000598.

Analysis of Biohaven Pharmaceutical Holding Co Offering

On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Biohaven Pharmaceutical Holding Co sold 50.00% of the offering. The financing is still open. The average investment size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 7,094.27% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this financing is set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Biohaven Pharmaceutical Holding Co Also

The Form D signed by Vladimir Coric might help Biohaven Pharmaceutical Holding Co Ltd.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment